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Insulin, the primary hormone regulating the level of glucose in the bloodstream,
modulates a variety of cellular and enzymatic processes in normal and diseased
cells. Insulin signals are processed by a complex network of biochemical inter-
actions which ultimately induce gene expression programs or other processes
such as translation initiation. Surprisingly, despite the wealth of literature on in-
sulin signaling, the relative importance of the components linking insulin with
translation initiation remains unclear. We addressed this critical question by de-
veloping and interrogating a family of mathematical models of insulin induced
translation initiation. The insulin network was modeled using mass-action ki-
netics within an ordinary differential equations (ODEs) framework. Model pa-
rameters were estimated, starting from an initial best fit parameter set, using
24 experimental data sets taken from literature. The residual between model
simulations and each of the experimental constraints was simultaneously min-
imized using the multiobjective POETs algorithm. Sensitivity and robustness
analysis were used to identify the key regulatory components of the network
under different operational conditions. Our analysis suggested that without in-
sulin, a balance between the pro-initiation activity of the GTP-binding protein
Rheb and anti-initiation activity of PTEN controlled basal initiation. On the
other hand, in the presence of insulin a combination of PI3K and Rheb activ-
ity controlled inducible initiation, where PI3K was only critical in the presence
of insulin. Other well known regulatory mechanisms governing insulin action,
for example IRS1 negative feedback, modulated the relative importance of PI3K
and Rheb, but did not fundamentally change the signal flow.
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CHAPTER 1
INTRODUCTION
1.1 Paths towards systems biology
The unfolding of events in the life cycle of an organism exhibits an admirable
regularity and orderliness, unrivaled by anything we meet with in inanimate matter.
We find it controlled by a supremely well-ordered group of atoms, which represent only
a very small fraction of the sum total in every cell. Moreover, from the view we have
formed of the mechanism of mutation we conclude that the dislocation of just a few
atoms within the group of ‘governing atoms’ of the germ cell suffices to bring about a
well-defined change in the large-scale hereditary characteristics of the organism. These
facts are easily the most interesting that science has revealed in our day.
- Erwin Schro¨dingerWhat is Life?
(Cambridge University Press, 1944)
When Erwin Schro¨dinger wrote his famous treatise, What is Life?, he was
profoundly interested in a seeming paradox observed in biological systems
[103]. In chemistry and physics, molecular behavior is fundamentally gov-
erned by entropic forces: chaos is favored, order is not. Interestingly, these
fields have shown that underlying disorder can in fact result in a population-
averaged behavior that is quite orderly. This ”order from disorder” paradigm
not only follows from a thermodynamic basis but also fits nicely with the seem-
ingly orderliness of day-to-day events (i.e. apples always fall vertically towards
the ground). Biological systems on the other hand, are observed to be quite
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different. Schro¨dinger was troubled by the underlying order of biological sys-
tems. Whereas the order observed in physics was a result of random events,
biology resulted from a “well-ordered group of atoms” who’s global behavior
was both surprisingly ordered and extraordinarily complex. This ”order-from-
order” paradigm seemed out of place next to the contrasting ”order from dis-
order” paradigm of the other sciences. Though perhaps years before his time,
echoes of Schro¨dinger’s questions continue to be heard even today. How do
biological systems fundamentally function? How does a small population of
‘governing atoms’ lead to biological diversity? What, at its truly fundamental
level, is life?
1.1.1 Molecular biology and biotechnology
These questions began to find answers through the rapid growth of molecular
biology in the 1940’s, 50’s and 60’s. Discoveries in this time period firmly es-
tablished molecular biology as a field that could provide unique insights into
the function of biological systems. Perhaps the most significant discoveries of
this time period involved the discovery of DNA structure and function. In 1944,
Oswald Avery identified DNA as the genetic material of bacterial cells [4]. Eight
years later, Alfred Hershey and Martha Chase, confirmed this result by show-
ing that a bacteriophage was simply a container that held its genetic material,
a material identified as DNA [44]. Later in 1953, Jim Watson and Francis Crick
demonstrated the double-helix structure of DNA and the complementary bind-
ing of its four different base pairs [128]. The correspondence of DNA sequence
to amino acid sequence of proteins was established by studies performed by
Vernon Ingram and Crick in 1957. In the years from 1957 to 1960, Francois Jacob
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and Jacques Monod identified the regulatory elements of lactose induction in
Escherichia coli [51]. The results from these studies are now infamously known
as the LAC operon.
The 1970s saw the emergence of genetic engineering and biotechnology. Site-
specific restriction enzymes, the workhorses of molecular biology [86], were
first discovered by Hamilton O. Smith in 1970 [106]. One year later, Danna and
Nathans showed that DNA cleaved by restriction enzymes could be separated
by size using gel electrophoresis [22]. It was not long after these pioneering
studies that recombinant DNA and biotechnology began to emerge [65, 49, 19].
In 1982, the US Food and Drug Administration approved Eli Lily’s ‘human’-
insulin, the first commercially available drug produced by recombinant DNA
technology [54]. This time period also witnessed the growth of DNA sequenc-
ing technology. In 1977, Sanger et al. developed a method for determining the
nucleotide sequence of DNA [95]. This process was later improved by Hood
and colleagues in 1986 [112] and then automated by Applied Biosystems in
1987. The powerful DNA amplification technique now known as Polymerase
Chain Reaction (PCR) was developed by Kary Mullis in 1983 [7].
1.1.2 The birth of ‘omics’ data sets
Throughout the following decade into the mid 1990s, further automation of bi-
ological assays allowed the generation of genome scale ‘omics’ data sets. In
1995, the entire genome of Haemophilus influenzae was sequenced, a significant
achievement marking a notable transition in the nature of biological research
[29]. In the next year, microarray analysis emerged as a method to asses the rel-
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ative abundance of different RNA transcripts within the cell [99, 17]. This time
period also witnessed the rise of proteomic data sets, measurements of each
protein expressed by the genome [77]. Seemingly overnight, biological research
was transformed from a historically data-poor field to one that was data-rich.
Biologists discovered that these ‘omics’ data sets could describe the levels of
virtually all biomolecules in cell [55].
The paramount accomplishment of all these ‘omics’ data sets was the se-
quencing of the human genome, a decade long process eventually completed in
2001 by Venter et al. [124]. Yet despite this triumph of biological research, Venter
et al. rightfully acknowledge that sequencing the human genome was only the
beginning,
“The next steps are clear: We must define the complexity that ensues when
this relatively modest set of about 30,000 genes is expressed . . . The sequence
is only the first level of understanding of the genome. All genes and their
control elements must be identified; their functions, in concert as well as
in isolation, defined; their sequence variation worldwide described; and the
relation between genome variation and specific phenotypic characteristics
determined. Now we know what we have to explain.”
As ‘omics’ changed the landscape of biological research, researchers were
facedwith the challenge of interpreting thesemassive data sets. It was no longer
sufficient to simply identify the the levels genes, mRNA and proteins in a cell.
Researchers began to ask how these many signals were integrated together to
generate behavior of the whole: how does global behavior form from the func-
tion of its individual parts? The stage was set for the emergence of a new field
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that sought to understand biology at a global, systems-level scale. The answer
was systems biology, a field to whom we now turn.
1.2 Systems Biology
1.2.1 An overview of systems biology
The goal of systems biology is to develop an understanding of biology at the
systems level. In contrast to the reductionist approaches of molecular biology,
systems biology adopts an integrative paradigm that seek to understand how
large numbers genes and proteins interact together. Hiroaki Kitano, the self
proclaimed father of systems biology writes,
“Identifying all the genes and proteins in an organism is like listing all the
parts of an airplane. While such a list provides a catalog of the individ-
ual components, by itself it is not sufficient to understand the complexity
underlying the engineered object. We need to know how these parts are
assembled to form the structure of the airplane.” [59]
This is the aim of systems biology: to move beyond a simple parts list to an un-
derstanding of how each part integrates together to form behavior of the whole.
In other words, systems biology offers an opportunity to understand how phe-
notype results from genotype. In the words of Alan Aderem, co-founder of the
Institute of Systems Biology, ”Systems biology is a comprehensive quantitative
analysis of the manner in which all the components of a biological system inter-
act functionally over time” [1]. Marc Krischner, the chair of the Department of
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Systems Biology at Harvard, writes, ”systems biology is the study of the behav-
ior of complex biological organization and processes in terms of the molecular
constituents” [57].
In order to gain insight into global systems behavior, both experimental
and computational approaches are necessary. Generally, the focus of experi-
mental systems biology is to improve high-throughput genomic and proteomic
platforms. This involves developing faster, cheaper and more accurate assays
that can give quantitative information about the dynamic state of a biologi-
cal system [46]. Experimental approaches also aim to clarify the mechanisms
and pathways of cellular signaling and gene regulatory logic [59]. Computa-
tional approaches generally fall in two main branches, knowledge discovery (or
data-mining) and simulation-based analysis [58]. In knowledge discovery, the
huge ‘omics’ data sets are interrogated using computational techniques in order
to unearth systems behavior (i.e. inference of gene regulatory networks from
mRNA expression profiles). Simulation-based analysis are used to explore sys-
tems properties that elude experimental observation. Simulation-based analy-
sis is used to generate hypothesis that can be validated by further experimental
studies [58]. In systems biology, both experimental and computational tech-
niques are necessary. Systems biology would cease to function effectively if
either of these approaches were divorced from the other.
1.2.2 Systems biology and its successes
In the past several years, systems biology has seen many successes. The scope
of ‘omics’ data sets have expanded dramatically beyond the genome, transcrip-
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tome and proteome. New high-throughput methods have been developed to
determine both DNA-protein [11, 56, 40] and protein-protein interaction data
[20, 14, 111]. Computational approaches have been developed to use this in-
teraction data to infer regulatory [5] and protein-protein interaction networks
[52, 84]. Other computational approaches have been used to decompose these
networks into modules to identify organizational principles and infer regions of
network activity [130, 115]. ‘Omics’ data has also been used to develop genome
scale models of an entire cell. These genome scale models have shown util-
ity at identifying systems properties and guiding experimental design [80, 83].
Systems biology has also shown usefulness in developing improved screens for
drug discovery [13, 12].
Another important area of research in systems biology is the development of
mechanistic models of biological systems. These models have clarified complex
dynamic behavior of signaling events like the MAPK cascade and apoptosis
[102, 97, 32]. Mechanistic models can also be used to understand network ro-
bustness and fragility. Robustness is defined by the ability of a network to main-
tain performance in the face of perturbations and uncertainty [110]. Though ro-
bustness has been known for years in control engineering [89], recent work has
identified biological signaling networks as robust [6, 2]. Further, Carlson et al.
have shown that networks can be robust to some perturbations while fragile to
others [15]. Computational methods have been shown to identify regions ro-
bustness and fragility within signaling networks [109] and can be used to iden-
tify the important interactions in signaling networks. The insight gained by
these models can help researchers to develop better hypothesis and to perform
more insightful experiments.
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CHAPTER 2
MECHANISTIC MODEL OF INSULIN-MEDIATED EUKARYOTIC
TRANSLATION INITIATION
2.1 Introduction
Insulin, the primary hormone regulating the level of glucose in the bloodstream,
modulates a variety of cellular and enzymatic processes in normal and diseased
cells [133, 73, 21, 88, 101, 131, 26]. The modulation of cellular function by in-
sulin and insulin-like growth factors I/II (IGF-I/II) is a highly complex process,
involving negative feedback and signal integration [78, 28, 116, 92, 91, 85, 67].
Insulin and IGF-I/II interact with insulin receptors (IR), and type I/II IGF recep-
tors (IGF-IR/IIR) in addition to other hybrid transmembrane receptors [116].
These interactions ultimately induce gene expression programs or other pro-
cesses such as translation initiation. Translation rates of many cell-cycle and
survival proteins are modulated by growth factor, hormone and other mito-
genic signals [8]. Insulin induces the activation of class I Phosphoinositide 3-
kinases (PI3Ks), which in turn activate the serine/threonine protein kinase Akt
and the mammalian target of rapamycin (mTOR). The PI3K/Akt/mTOR sig-
naling axis is important to a variety of cellular programs, including apoptosis
[129] and translation initiation. Activation of the PI3K/Akt/mTOR axis ulti-
mately results in the phosphorylation of eukaryotic translation initiation factor
4E-binding protein (4E-BPx) family members [35]. Phosphorylation of 4E-BPx
causes the release the eukaryotic translation initiation factor 4E (eIF4E), which
is critical to directing ribosomes to the 7-methyl-guanosine cap structure of eu-
karyotic mRNAs. Previously, the availability of eIF4E has been shown to be rate
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limiting for translation initiation in many eukaryotic cell-lines [132, 8]. Given
its central role in cell biology, evolutionarily optimized infrastructure like trans-
lation might be expected to be robust or highly redundant. Surprisingly, dereg-
ulated translation, especially involving growth-factor or insulin induced initia-
tion mechanisms, has been implicated in a spectrum of cancers [9].
Despite the wealth of literature on insulin signaling, the relative importance
of the components linking insulin with translation initiation remains unclear.
Many investigators have explored this question using both experimental and
computational tools. Taniguchi et al. proposed three criterion to identify the
critical nodes of insulin signaling: network divergence, degree of regulation and
potential crosstalk [116]. Using these criteria, they identified insulin-receptor
(IR), PI3K and Akt as the critical nodes of insulin action. Our understanding of
the insulin signaling interactome has also continued to evolve. For example,
Caron et al. recently published a comprehensive map of the mTOR signaling
network, including a detailed portrait of insulin-induced mTOR activation and
its downstream role in translation initiation [16]. Several insightful mathemati-
cal models of insulin-signaling have also been published [27, 23, 10, 47]. While
these models vary in their focus and biological scope, none has exclusively fo-
cused on how insulin stimulation induces translation initiation. This particu-
lar question was addressed by Nayak et al., who analyzed a family of detailed
mathematical models of growth-factor and insulin-induced translation initia-
tion [75]. The Nayak et al. study suggested that Akt/mTOR were structurally
fragile, and likely the key elements integrating growth factor signaling with
translation initiation. Thus, the Nayak study et al. at least partially supported
the Taniguchi et al. hypothesis. However, the Nayak et al. model neglected sev-
eral key features of insulin processing, e.g., negative feedback of IR resulting
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from mTOR activity.
The objective of this study was to rank-order the importance of components
of insulin-induced translation initiation using computational tools. Toward this
objective, we developed and analyzed an ensemble of mechanistic mathemati-
cal models of insulin induced translation initiation that was a significant exten-
sion of our previous work [75]. First, we expanded the original model connec-
tivity to include a detailed description of the regulation and activity of insulin,
insulin-like growth factor and PDGF receptor family members (including nega-
tive feedback). Second, we refined the description of the phosphorylation state
of Akt and its downstream role in the activation of the mTORC1 and mTORC2
complexes. Lastly, we used newmodel estimation and interrogation techniques
to generate and analyze an uncorrelated population of initiation models that
were simultaneously consistent with 24 qualitative and quantitative data sets.
Interrogation of this model population, using sensitivity and knockdown anal-
ysis, identified an insulin-dependent switch that controlled translation initia-
tion. Without insulin, a balance between the pro-initiation activity of the GTP-
binding protein Rheb and anti-initiation activity of PTEN controlled basal initi-
ation. Rheb knockdown simulations confirmed decreased initiation in the ma-
jority of the model population. Surprisingly, we also identified amodel subpop-
ulation in which deletion of Rheb or mTORC2 components increased initiation.
In these cases, removal of Rheb or mTORC2 components relieved a rate-limiting
bottleneck e.g., constrained levels of GTP, leading to increased initiation. On the
other hand, in the absence of insulin, translation initiation increased for all mod-
els in the population following a PTENdeletion. In the presence of insulin, Rheb
and PTEN were no longer the dominant arbiters of initiation; a combination of
PI3K and Rheb activity controlled inducible initiation, where PI3Kwas only crit-
10
ical in the presence of insulin. PI3K deletion in the presence of insulin removed
the ability of the network to process insulin signals, but did not remove initi-
ation altogether. PI3K deletion reduced initiation to approximately 60% of its
maximum level. Interestingly, the relative contribution of PI3K versus Rheb to
the overall initiation level could be tuned by controlling the level of IRS1 feed-
back. In the absence of feedback, PI3K was more important than Rheb to signal
propagation, while the opposite was true in the presence of feedback. Taken to-
gether, our modeling study supported the Taniguchi et al. hypothesis that PI3K
was a critical node in the insulin-induced initiation network. However, we also
found that the role of PI3K was nuanced; PI3K in combination with Rheb-GTP
controlled initiation in the presence of insulin, while the combination of PTEN
and Rheb controlled the rate of basal initiation.
2.2 Results
2.2.1 Translation initiation model connectivity.
The translation initiation model consisted of 250 protein or mRNA species inter-
connected by 573 interactions (Fig. 2.1). The model described the integration of
insulin and growth-factor signaling with 5′-cap recognition and 80S assembly.
While other translation initiation mechanisms exist in eukaryotes, here we fo-
cused on cap-mediated translation as the dominant translation mechanism [71].
The model interactome was taken from literature (available as an SBML file in
the supplemental materials); the connectivity of insulin- and growth-factor in-
duced translation initiation has been extensively studied [67, 50]. The model
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interactomewas not specific to a single cell-line. Rather, it was a canonical repre-
sentation of the pathways involved in insulin and growth-factor induced initia-
tion. Binding of insulin or IGF-I/II with IR or IGF-I/IIR promotes the autophos-
phorylation of the cytosolic domains of these receptors at tyrosine residues.
Receptor autophosphorylation promotes the formation of adaptor complexes,
which are anchored in place by insulin receptor substrate (IRSx) family mem-
bers; IRSx are required for the assembly of adaptor complexes involving the
Shc, SoS, Grb2 and Ras proteins [105, 104, 87]. In the model we considered
only the IRS-1 protein, and neglected other IRSx family members. Adaptor
complex formation ultimately culminates in the activation of the catalytic sub-
unit of PI3K. Among their many roles, PI3Ks catalyze the phosphorylation of
the phospholipid PIP2 to form PIP3 [131]. PIP3 is critical to the localization
of 3-phosphoinositide-dependent kinase 1 (PDK1) to the membrane, where it
phosphorylates the master kinase Akt at Thr308 [72]. Akt is further phosphory-
lated at Ser473 by the rictor-mammalian target of rapamycin (mTORC2) protein
[96]. Once phosphorylated, Akt promotes translation initiation by directly or
indirectly activating the mTORC1 protein [133]. Akt directly activates mTORC1
through a novel binding partner known as PRAS40 [94, 38]. However, mTORC1
can also be activated by the GTP bound form of the Ras homologue enriched in
brain (Rheb) protein. In the absence of insulin, Rheb is regulated by the tuberous
sclerosis complex tumor-suppressor protein TSC1/2, which has GTPase activat-
ing protein (GAP) activity. Akt directly phosphorylates TSC1/2 which inhibits
its GAP activity and allows Rheb-mediated activation of mTORC1 [48, 70]. Ac-
tivated mTORC1 plays two key roles in translation initiation; first, it activates
ribosomal protein S6 kinase beta-1 (S6K1) and second it phosphorylates eukary-
otic translation initiation factor 4E-binding protein (4E-BPx) family members
12
[41]. In this study we included only 4E-BP1 and modeled a single deactivat-
ing phosphorylation site. Phosphorylated 4E-BP1 releases eIF4E, which along
with other initiation factors, is critical to directing ribosomes to the 7-methyl-
guanosine cap structure of eukaryotic mRNAs [50].
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Figure 2.1: Schematic of signaling network. Growth factors result in recep-
tor dimerization and formation of adaptor complexes which
activate PI3K. PI3K signals through PIP2/3 to activate Akt. Ac-
tivated Akt activates mTORC1 either directly or by phospho-
rylating TSC1/2, an inhibitor of Rheb. Activated mTORC1 can
phosphorylate 4EBP1 and activate S6K1, two necessary check-
points for translation initiation. mTORC1 can also phospho-
rylate IRS1, a form of negative feedback which inhibits forma-
tion of the adaptor complex and attenuates insulin-mediated
signaling. See Table A.1 for full species names.
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There are many mechanisms which attenuate insulin and growth-factor in-
duced translation initiation. First, several proteins control insulin signal prop-
agation by disrupting adaptor complex formation. For example, we included
in the model tyrosine phosphatases and competitive inhibitors such as PTP1B,
SHP2, Grb10 and SOCS1/3 which interfere with adaptor complex formation
and activity [116, 25, 74, 120]. Second, several mechanisms control PIP3 forma-
tion, PDK1 recruitment and Akt phosphorylation [116]. In the model we in-
cluded the phosphatase and tensin homolog (PTEN) protein, which is known
to dephosphorylate PIP3 [113], and SH2 (Src homology 2)-containing inosi-
tol phosphatase-1 (SHIP1) which hydrolyses the 5′-phosphates from PIP3 [63].
Lastly, S6K1 can phosphorylate IRS-1 at Ser318, thus inhibiting its function [37].
This S6K1/IRS-1 feedback mechanism has been shown to be important in in-
sulin resistance and cancer [67, 122, 121, 24].
2.2.2 Estimating an ensemble of translation initiation models
using POETs.
Translation initiation was modeled using mass action kinetics within an ordi-
nary differential equation (ODE) framework. ODEs and mass-action kinetics
are common methods of modeling biological pathways [32, 102, 18, 42]. How-
ever, ODEs require a large number of unknownmodel parameters. For the initi-
ation model, these parameters were not uniquely identifiable (data not shown).
Instead, we estimated an experimentally constrained population of parameters
using multiobjective optimization. Model parameters were estimated, starting
from an initial best fit parameter set, using 24 experimental data sets taken from
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literature (Table 2.1). Both in-vitro and in-vivo, dynamic and steady state mea-
surements from multiple cell-lines were used for model training. The residual
betweenmodel simulations and each of the experimental constraints was simul-
taneously minimized using the multiobjective POETs algorithm [107]. In total,
823 unknown parameters (573 kinetic parameters and 250 initial conditions)
were estimated using the POETs. We used a leave-three-out cross-validation
strategy to independently estimate the prediction and training error during pa-
rameter estimation (Table 2.1). Three of the twenty-four objectives were re-
served for validation, while the remaining 21 were used for model training.
Thus, we estimated eight model families, each of which was trained and val-
idated on different experimental data. Additionally, a random parameter set
control was run to check the training/prediction fitness above random (Table
2.1). The random control was generated from 100 random parameter sets with
parameter values independent of the nominal set. For 21 of the 24 objectives,
the model prediction error was statistically significantly better than the random
control (t-test, p-value = 0.05). Two remaining objectives (O4 and O12) trained
on species heavily constrained by other objective functions e.g., pAkt(Thr308
and Ser473). POETs generated 18,886 probable models with Pareto rank ≤ 4.
The performance of 5,818 rank-zero models against selected training objectives
is shown in Fig. 2.2. The majority of objective function pairs were uncorrelated
e.g., O4×O13 or O12×O13. Uncorrelated objectives suggested the ensemble in-
dependently described each of the training objectives. Other objective function
pairs were directly proportional e.g., O3×O11 or O9×O15. This trend suggested
complementary training data. Interestingly, certain objectives were inversely
proportional e.g., O12×O14. For these pairs, the model was unable to simul-
taneously fit both training data sets. Surprisingly, these objectives were iden-
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Figure 2.2: Pareto Optimization. The Scaled Simulation Error (SSE) for
rank-zero sets identified by POETs were plotted for each ob-
jective function pair. 14 of the total 24 sets used for model
training are shown. If a objective function was chosen by cross-
validation for prediction, the SSE of that objective function was
set to zero and disregarded when ranking other sets. Red point
indicates error of nominal set.
tical protein measurements in similar experiments pAkt(Thr308) O9×O12 and
pS6K1(Thr389) O3×O14, taken either in different cell-lines or different labs. This
suggested conflicts in the data e.g., cell-line variation or differences in specific
laboratory protocols, rather than structural inaccuracies in the model, were re-
sponsible for the inverse relationship.
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Table 2.1: Objective function list along with species, cell-type, cellular compart-
ment, nominal error, training error, prediction error, random error with a ran-
domly generated parameter set and the corresponding literature reference.
O# species cell type nominal training prediction random source
O1 PI3K Activity 3T3-L1 cells 0.01 0.01 ± 0.00 0.01 ± 0.00 0.67 ± 0.20 [62]
O2 PIP3 3T3-L1 cells 0.00 0.00 ± 0.00 0.00 ± 0.00 0.84 ± 0.08 [62]
O3 p-S6K1(T389) 3T3-L1 cells 0.39 0.17 ± 0.15 0.27 ± 0.24 1.55 ± 0.49 [38]
O4 AKT act (S473) 3T3-L1 cells 0.38 0.30 ± 0.23 0.53 ± 0.29 0.50 ± 0.38 [38]
O5 IRS1 3T3-L1 cells 0.43 0.47 ± 0.62 1.37 ± 0.71 0.56 ± 0.58 [38]
O6 AKT act (S473) 393T cells 0.06 0.28 ± 0.32 0.43 ± 0.35 1.10 ± 0.31 [38]
O7 AKT act (S473) C2C12 myotubes 0.05 0.12 ± 0.13 0.12 ± 0.13 0.69 ± 0.11 [61]
O8 p-S6K1 (T421/S424) C2C12 myotubes 0.20 0.18 ± 0.07 0.20 ± 0.10 0.47 ± 0.22 [61]
O9 Act AKT (T308) HUVEC cells 1.21 0.78 ± 0.38 0.94 ± 0.36 1.20 ± 0.79 [43]
O10 IRS1-P (S636/639) L6 Myotubes 1.34 1.17 ± 0.37 1.13 ± 0.35 1.28 ± 0.38 [119]
O11 p-S6K1 (T389) L6 Myotubes 0.98 0.27 ± 0.33 0.55 ± 0.64 2.95 ± 0.51 [119]
O12 Act Akt (T308) L6 Myotubes 0.93 0.62 ± 0.36 0.71 ± 0.34 0.84 ± 0.48 [119]
O13 IRS1-P (S636/639) L6 Myotubes 1.24 1.07 ± 0.38 1.29 ± 0.31 1.35 ± 0.36 [119]
O14 p-S6K1 (T389) L6 Myotubes 2.36 2.02 ± 0.43 2.26 ± 0.24 1.95 ± 0.38 [119]
O15 Act Akt (T308) L6 Myotubes 0.97 0.39 ± 0.35 0.48 ± 0.33 0.87 ± 0.82 [119]
O16 p-S6K1 (T389) RhoE 3T3 cells 1.33 0.28 ± 0.33 0.21 ± 0.25 2.94 ± 0.54 [125]
O17 c4EBP-P (S65, T37/46) RhoE 3T3 cells 0.37 0.57 ± 0.33 0.85 ± 0.38 1.76 ± 0.43 [125]
O18 Cap-Met-Puro rabbit reticulocytes 0.46 0.42 ± 0.46 0.86 ± 0.73 1.24 ± 0.71 [66]
O19 43S-mRNA rabbit reticulocytes 0.19 0.37 ± 0.39 0.57 ± 0.47 1.14 ± 0.64 [66]
O20 AKT act (S473) A14 NIH 3T3 cells 1.12 0.98 ± 0.23 0.99 ± 0.23 1.16 ± 0.15 [34]
O21 p-S6K1 (T389) A14 NIH 3T3 cells 1.20 0.57 ± 0.29 0.57 ± 0.23 0.69 ± 0.21 [34]
O22 Rheb HeLa cells 0.00 0.15 ± 0.83 0.10 ± 0.71 1.99 ± 0.09 [34]
O23 p-S6K1 (T389) HeLa cells 0.13 0.14 ± 0.11 0.24 ± 0.23 0.77 ± 0.58 [34]
O24 c4EBP1-P (T70) HEK293 cells 0.25 0.34 ± 0.26 0.62 ± 0.41 0.90 ± 0.22 [34]
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The ensemble of translation models recapitulated diverse training data
across multiple cell-lines (Table 2.1). The key indicators of translation initiation
in eukaryotes are the phosphorylation of S6K1 and 4E-BP1 [41]. Both Tzatos
et al. and Villalonga et al. performed insightful studies exploring the dynam-
ics of S6K1 and 4E-BP1 phosphorylation in L6 Myotubes and RhoE 3T3 cells
[119, 125]. The ensemble recapitulated these observations (train = 0.27 ± 0.33,
rand = 2.95± 0.51; train = 0.57± 0.33, rand = 1.76± 0.43) (Fig. 2.3A and 2.3B). Fur-
ther, the ensemble of models was able to respond accurately to growth factors
insulin and FBS (Fig. 2.3A and 2.3B). The model was also able to recapitulate
IGF1 induced responses (train = 0.12 ± 0.13, rand = 0.69 ± 0.11; train = 0.18 ± 0.07,
rand = 0.69± 0.11) (Fig. 2.3E and 2.3F). Lorsh et al. studied the dynamics of ribo-
somal assembly in rabbit reticulocytes and identified key kinetic parameters in
both 43S and 80S assembly [66]. Most importantly, Lorsh et al. discovered that
the formation of the tertiary complex (eIF2:GTP:Met-tRNA) was the rate limit-
ing step in 80S* formation. Our model captured the 80S* dynamics, including
this crucial lag phase in the first two minutes of stimulation (train = 0.42 ± 0.46,
rand = 1.24 ± 0.71) (Fig. 2.3C). The effect of inhibitors was used to train the net-
work for different modes of operation. In the absence of insulin, PI3K is not ac-
tivated and pAkt (Ser473) levels remain very low (Fig 2.3D, lane 1). Upon stim-
ulation with insulin, PI3K activation results in increased levels of pAkt (Ser473)
(Fig 2.3D, lane 2). Wortmanin is a PI3K inhibitor that prevents signaling down-
stream of PI3K to Akt. Thus, in the presence of insulin and wortmanin, pAkt
(Set473) levels significantly decrease (Fig 2.3D, lane 3). While our model qual-
itatively captures this decrease, the model predicts levels of pAkt (Ser473) that
are higher than those observed experimentally. Though our model was not ex-
plicitly constrained on levels of mTORC1/2, significant constraints were placed
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on the species immediately upstream and downstream of mTORC1/2, namely
pAkt (Ser473) and S6K1. Experimental data using rapamycin, a common in-
hibitor of mTORC1, was also used to constrain mTORC1 mediated signaling.
In the absence of insulin, levels of pAkt(Ser473) and S6K1(Thr421/Ser424) are
very low (Fig 2.3E/F, lanes 1). Addition of insulin results in increased activity
of these species. Upon rapamycin addition, mTORC1 is impaired and levels of
phosphorylated S6K1 decrease (Fig. 2.3E, lane 3). However, because of its posi-
tion upstream of mTORC1, pAkt(Set473) levels are unimpaired (Fig. 2.3E, lane
3).
The predictive ability of the model was tested by comparing model simula-
tions with in-vivo and in-vitro data sets not used for training (Table 2.2). For
all five prediction data sets, the model demonstrated errors statistically sig-
nificantly better that the random control (t-test, p-value = 0.05). Data from
Lorsh et al. was used to validate the dynamics of intermediate ribosomal com-
plexes [66]. The level of 43S mRNA was quantified using both GTP and a non-
degradable GTP-like homologue GMP-PNP (Fig. 2.4A). Data involving GMP-
PNP was used for training while data involving GTP was used only for vali-
dation. The model was able to accurately predict this data (pred = 0.52 ± 0.40,
rand = 0.82 ± 0.51). Garami et al. explored the insulin-mediated activation of
Rheb and the role of its inhibitors TSC1/2 [34]. In another part of their study,
Garami et al. investigated the effect of wortmanin and rapamycin on the ra-
tio of GTP to GDP bound Rheb [34]. While our model captured the qualitative
trends, we over-predicted the percentage of GTP bound Rheb (pred = 0.22±0.11,
rand = 0.42 ± 0.01) (Fig. 2.4B). The model also failed to predict the sustained
levels of Rheb-GTP in the presence of rapamycin . This suggested that the sus-
tained levels of pAkt(Ser473) (observed in Figure 2.3E) did not correlate with
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Figure 2.3: Ensemble Performance Against Training Data. Performance of
each member of the model ensemble was compared against
data. Dotted lines represent ensemble mean, shaded regions
represent 99.9% confidence interval of deviation of mean. A.
Time course data for p70S6K1 phosphorylation in response
to insulin stimulation (L6 Myotubes) B. Time course data for
c4EBP1 phosphorylation in response to FBS (RhoE 3T3 cells) C.
In vitro time course of 80S complex measured by puromycin
assay. (rabbit reticulocyte) D. pAkt(Ser473) levels at 20 min-
utes in the presence and absence of insulin and wortmanin, se-
lective PI3K inhibitor. (393T cells) E,F. pAkt(Set473) and Acti-
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increased Rheb-GTP activity. Garami et al. also measured the levels of GTP
bound Rheb in both wild-type and TSC2 knockout cells. Because of TSC2’s reg-
ulatory role in mediating Rheb-GTP levels, a TSC2 knockout had significantly
increased Rheb-GTP levels (pred = 0.10 ± 0.03, rand = 0.09 ± 0.06) (Fig. 2.4C).
Lastly, the model predicted the levels of 4E-BP1 bound eIF4E in response to
heat shock (pred = 0.51 ± 0.33, rand = 1.67 ± 1.17) (Fig. 2.4D) [126]. Heat shock
inhibits translation initiation through de-phosphorylation of 4E-BP1; because
the model was not trained on stress-induced translation-inhibition, this result
demonstrated the predictive power of the model population and the utility of
using model populations for the prediction of the behavior of novel stimuli.
Table 2.2: Blind Prediction list along with species, cell-type, prediction error,
random error with a randomly generated parameter set and the corresponding
literature reference.
Prediction# species cell type compartment prediction random source
P1 43S-mRNA (GTP) rabbit reticulocytes in vitro 0.52 ± 0.40 0.82 ± 0.51 [66]
P2 Rheb-GTP A14 NIH 3T3 cells Total lysate 0.22 ± 0.11 0.42 ± 0.01 [34]
P3 Rheb-GTP A14 NIH 3T3 cells Total lysate 0.10 ± 0.03 0.09 ± 0.06 [34]
P4 eIF4E:4EBP1 CHO K1 cells Total lysate 0.51 ± 0.33 1.67 ± 1.17 [126]
P5 pAkt(Ser473) HEK293 cells Total lysate 0.27 ± 0.09 0.72 ± 0.09 [34]
2.2.3 Sensitivity and robustness analysis identified robust and
fragile features of the initiation architecture.
We generated falsifiable predictions about the fragility or robustness of struc-
tural features of the initiation architecture using sensitivity and robustness anal-
ysis. First order sensitivity coefficients were computed for 40 parameter sets
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Figure 2.4: Model Predictions. Predictive ability of model ensemble was
assessed by comparing model performance with novel experi-
mental data. Dotted lines represent ensemble mean, shaded re-
gions represent 99.9% confidence interval of deviation of mean.
A. In vitro time course for formation of 43S-mRNA complex. A
slowly-hydrolyzable GTP homologue(GMP-PNP) was used in
place of GTP to isolate formation of this intermediate complex.
GMP-PNP data was used for trainingwhile GTP data was used
for validation. B. Percent of Rheb-GTP to Rheb-GDP in the
presence of insulin, wortmanin and rapamycin.(A14 NIH 3T3
cells) C. Percent of Rheb-GTP to Rheb-GDP in wildtype and
TSC2 lacking cells. (MEF cells) D. 4EBP1 bound EIF4E in the
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selected from the ensemble (materials and methods), time-averaged and rank-
ordered for the 250 species in the model, in the presence and absence of insulin
and IRS-1 feedback. The sensitive components of insulin signaling shifted from
Rheb in the absence of insulin to a combination of Rheb and PI3K in the presence
of insulin. Sensitivity coefficients were calculated with and without insulin over
the complete 100 min response (Fig. 2.5A). Globally, processes involved with
80S formation were consistently ranked among the most sensitive, irrespec-
tive of insulin. However, the sensitivity of other signal processing components
changed with insulin status. For example, without insulin, Rheb/Rheb-GDP
were highly fragile (NSS rank ≥ 0.25), while PI3K, PIP2, PIP3 and PTEN were
highly robust (NSS rank ∼ 0.0). Surprisingly, the relative sensitivity of these
network components changed in the presence of insulin. While the fragility
of Rheb/Rheb-GDP shifted upward with insulin, the sensitivity of PI3K and
its downstream complexes increased dramatically (NSS rank ≥ 0.45) following
insulin stimulation. This suggested that the combination of PI3K and Rheb ac-
tivity was critical to insulin action over the full 100 min time window. However,
it was unclear whether PI3K was always important, or if there was a temporal
window in which PI3K became important following insulin stimulation. To ex-
plore this question, we time-averaged the sensitivity coefficients over early- and
late-phase time periods following insulin stimulation (Fig. 2.5B). The 0-5minute
time period captured the initial network dynamics, while the 30-100 minute
time period captured the network at a quasi-steady state. Generally, network
components were more sensitive under dynamic operation (species beneath the
45o line), compared with steady-state. However, there were exceptions to this
trend. For example, PI3K, PTEN and TSC1/2 were equally sensitive in both
time frames, suggesting these species played important roles in both dynamic
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and steady-state signaling. On the other hand, the Rheb NSS rank decreased
from 0.6 to 0.25 as the network moved toward steady-state. Taken together, the
sensitivity results suggested that Rheb/Rheb-GDP activity controlled the back-
ground level of translation initiation while the PI3K axis in combination with
Rheb/Rheb-GDP regulated insulin-induced initiation.
IRS1 phosphorylation, a well known negative feedback mechanism [67, 122,
121, 24], attenuated PI3K sensitivity. We explored the role of IRS1 feedback by
comparing sensitivity coefficients under insulin stimulation in the presence and
absence of IRS1 feedback (Fig. 2.5C). The most significant change without feed-
back was the sensitivity of the IR:IRS1 and adaptor complexes (Fig. 2.5C, black
fill); IR:IRS1, which anchors the adaptor complex to the activated receptor and
is immediately upstream of PI3K activation, changed from NSS rank ' 0.04 to
0.32. The sensitivity of the PI3K/Akt signaling axis also increased in the ab-
sence of feedback (Fig. 2.5C, grey fill). Surprisingly, the sensitivity of Rheb and
many ribosomal components decreased in the absence of feedback. Similar re-
sults were observed when sensitivity coefficients were time averaged over the
0 to 5 min time window (Fig. 2.5D). These sensitivity calculations suggest that
IRS1 feedback plays a significant role in insulin signaling by modulating the
relative importance of PI3K versus Rheb. Thus, IRS1 feedback though not di-
rectly identified as a fragile regulatory motif, has significant effects on network
function.
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Figure 2.5: Sensitivity Analysis. Species with a high sensitivity rank-
ing are considered fragile while species with a low sensitivity
ranking are considered robust. A. Sensitivity ranking of net-
work species in the presence and absence of insulin. B. Time-
course Sensitivity ranking of network species. C,D. Sensitiv-
ity ranking of network species in the presence and absence of
IRS1 feedback. Black fill represents complexes containing IRS1,
Grey fill represents PI3K/Akt associated signaling. Sensitivity
valueswere time averaged over 0-100minutes and 0-5minutes,
respectively.
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2.2.4 Robustness analysis identified key regulators of translation-
initiation
Knockdown simulations were conducted for 92 proteins to estimate the func-
tional connectedness of the initiation network. The effect of the perturbations
were quantified by calculating the fold change in translational activity (α) for
each simulated knockout in the presence (Fig. 2.6A) and absence (Fig. 2.6B)
of insulin. Knockdown simulations were conducted using 400 models selected
from the ensemble based on CV and correlation (materials andmethods). Sensi-
tivity analysis suggested basal translation was governed by Rheb, while insulin-
induced initiation was governed by PI3K. Robustness analysis showed that per-
turbations in PI3K signaling, in the presence of insulin, restored initiation con-
trol to Rheb. Proteins were classified based on their impact on translational ac-
tivity: little or no effect (α ≈ 1, white fill), moderate decrease (α ≈ 0.6, dark grey),
critical (α ≈ 0, light grey) and increase (α > 1, black). Generally, knockdowns
in the presence of insulin were more likely to decrease initiation (Fig. 2.6A).
Knockdown analysis identified 24 proteins (or 26% of the network) that were
critical to translation initiation irrespective of insulin status; these critical com-
ponents included mTORC1, S6K1, several initiation factors and other ribosomal
components. Initiation was moderately reduced by disrupting species immedi-
ately upstream or downstream of PI3K; a moderate reduction in the presence of
insulin further demonstrates that initiation is governed by both PI3K and Rheb.
Lastly, deletion of TSC1/2 (negative regulator of Rheb) or 4E-BP1 (sequesters
the cap-binding protein eIF4E), increased initiation in the presence of insulin.
Interestingly, for several proteins the direction or magnitude of change in initi-
ation activity depended upon the presence or absence of insulin. For example,
27
PTEN deletion significantly increased initiation (α  1) in the absence of in-
sulin, but had no effect when insulin was present. On the other hand, PI3K
deletion had a moderate reduction in the presence of insulin, but only a small
effect in the absence of insulin (Fig. 2.6B). These results suggested that PI3K
and PTEN were conditionally fragile proteins; in the presence of insulin, PI3K
is critical signal processing node, while PTEN acts to restrain inadvertent basal
initiation. We further tested this hypothesis by exploring a Rheb knockdown.
Our expectation from sensitivity analysis was that a Rheb knockdown would
reduce initiation, irrespective of insulin status. However, paradoxically, Rheb
and mTORC2 subunit (sin1, rictor) knockdowns increased initiation.
We explored this result by examining the behavior of each individual mem-
ber of the ensemble (Fig. 2.6C). Following the deletion of PTEN, approximately
80% (or 323 of the 400 models sampled) had increased initiation in the absence
of insulin. Of these models, 16% (or 51 of 323) had at least a two fold increase in
translational activity. This result was expected, deletion of a protein species re-
sulted in a qualitatively similar change in initiation across the ensemble of mod-
els. However, for Rheb knockdowns, members of the ensemble demonstrated
qualitatively different behavior. For 84% (or 334 of 400) of the models sampled,
Rheb knockdowns significantly down-regulated initiation. Thus, the vast ma-
jority of models behaved as expected. Interestingly, 20 models (or 5% of the
models sampled) had increased translation initiation in the presence of a Rheb
knockdown, with 15 models demonstrating greater than a two-fold change (Fig.
2.6C). Thus, the model population estimated by POETs, contained models that
showed qualitatively different behavior. Histograms of sin1 and rictor knock-
downs showed a similar trend (results not shown). To explore this population
heterogeneity, we isolated parameter sets demonstrating contrasting qualitative
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Figure 2.6: Species Knockdowns. Simulated knockdowns were performed
by removing nodes from the stoichiometric matrix. The fold-
change in expression levels resulting from perturbations quan-
tified the impact of each knockdown. Calculations were per-
formed on all 400 members of the ensemble. A. Species knock-
downs in the presence of insulin. Simulated knockdowns re-
sulted in increased (black), constant (white), a moderately de-
creased (dark grey) or a severely decreased (light grey) trans-
lational levels. B. Species knockouts in the absence of insulin.
Simulated knockdowns resulted in increased (black), constant
(white), or decreased (grey) translational levels. C. Histogram
of translation levels across each member of parameter ensem-
ble. Asterisk indicates parameter sets that were selected for
further analysis. D. Alternative modes of network operation.
For a subset of the ensemble, the network demonstrates opera-
tional modes that can result in translation increases upon Rheb
or mTORC2 disruption. Asterisk indicates rate-limiting step.
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behavior. We explored flux vectors of these outlying parameter sets to better
understand the mechanistic effect of Rheb and rictor/sin1 knockouts. All of
the outlying models were in regions of parameter space where the association
between Rheb and GTP were very high. Strong Rheb/GTP binding resulted in
abnormally high signal flux to mTORC1 despite the inhibitory effects of TSC1/2
(Fig. 2.6D, top-left). Consequently, less GTP was available for the energy-
dependent steps of translation initiation (i.e. formation of eIF2-GTP-met-tRNA
tertiary complex). Additionally, strong association between Rheb and GTP re-
sulted in high levels of activated mTORC1 and S6K1. However, despite the
high levels of mTORC1, GTP-dependent pre-initiation reactions were rate limit-
ing (Fig. 2.6D, labeled*). Thus, Rheb knockdown released the network from its
GTP limitation and shifted the predominant signaling mode to mTORC2. This
shift in signaling, while lowering the activated mTORC1/S6K1 level, ultimately
resulted in higher levels of initiation (Fig. 2.6 bottom-left). On the other hand,
the rictor/sin1 knockdown behaved differently. The rate-limiting step for the
rictor/sin1 knockdowns was mTORC1 activation: more Rheb-GTP was present
than there was mTORC1 to be activated (Fig. 2.6D top-right). Thus, knockdown
of rictor/sin1 prevented the assembly of mTORC2 and freed the mTOR subunit
to be used for mTORC1 assembly. This shift toward mTORC1 assembly and
activation relieved the Rheb-GTP/mTORC1 bottleneck, resulting in increased
initiation.
2.3 Discussion
In this study we developed and analyzed a population of insulin- and growth-
factor induced translation initiation models. These models described the inte-
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gration of insulin and growth-factor signals with 80S assembly. We addressed
parametric uncertainty by identifying an uncorrelated population of parameter
sets consistent with 24 transient and steady-state data sets using multiobjective
optimization. The model family also predicted novel data sets not used during
model training. The population of initiation models was analyzed using sensi-
tivity and robustness analysis to identify the key components of insulin-induced
translation initiation. Without insulin, a balance between the pro-initiation ac-
tivity of the GTP-binding protein Rheb and anti-initiation activity of PTEN con-
trolled basal initiation. Rheb knockdown simulations confirmed decreased ini-
tiation in the majority of the model population. Surprisingly, we also identified
a model subpopulation in which deletion of Rheb or mTORC2 components in-
creased initiation. In these cases, removal of Rheb or mTORC2 components
relieved a rate-limiting bottleneck e.g., constrained levels of GTP, leading to in-
creased initiation. On the other hand, in the absence of insulin, translation initi-
ation increased for all models in the population following a PTEN deletion. In
the presence of insulin, Rheb and PTENwere no longer the dominant arbiters of
initiation; a combination of PI3K and Rheb activity controlled inducible initia-
tion, where PI3Kwas only critical in the presence of insulin. PI3K deletion in the
presence of insulin removed the ability of the network to process insulin signals,
but did not remove initiation altogether. PI3K deletion reduced initiation to ap-
proximately 60% of its maximum level. Interestingly, the relative contribution
of PI3K versus Rheb to the overall initiation level could be tuned by controlling
the level of IRS1 feedback. In the absence of feedback, PI3Kwasmore important
than Rheb to signal propagation, while the opposite was true in the presence of
feedback.
Our study identified an insulin-dependent switch that controlled transla-
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tion initiation. In the absence of insulin, initiation was controlled by a balance
between the pro-initiation activity of Rheb-GTP and the anti-initiation activity
of PTEN. Upon insulin stimulation, control of signaling shifted from PTEN to
PI3K. The cellular decision to choose either operational mode was highly frag-
ile. Perturbation of network components was observed to switch the network
between pro- and anti-initiationmodes. This paradigm is useful towards under-
standing various disease states. Yuan and Cantley have noted that every major
species in the PI3K pathway is mutated or over-expressed in a wide variety of
solid tumors [131]. Mutations in PIK3CA, the gene encoding the catalytic sub-
unit of PI3K, has been shown to induce oncogene signaling in human cancers
by causing constitutive PI3K signaling [93]. PTENmutations have also been im-
plicated in a wide variety of cancers [90]. Both PIK3CA and PTENmutations in-
duce a pro-initiation operational mode in the absence of growth factor. Further,
enhancement of Rheb activity can also induce a pro-initiation mode. Saucedo
et al. showed that Rheb over-expression resulted in increased translation, even
in the absence of insulin or other growth factors [98]. Malfunctions in Rheb
signaling in the form of both Rheb and TSC1/2 mutations are also frequently
observed in cancer [53, 64]. Our analysis suggests that all such malfunctions
are all due to a wrongly activated initiation program. We claim that the mech-
anistic basis of these malfunctions lies at the intersection of Rheb, PTEN and
PI3K mediated control. Our findings support the findings of Taniguchi et al.
and the identification of PI3K as a critical node in the insulin signaling network
[116]. Importantly however, we have shown that the role of PI3K is nuanced .
Whereas insulin-signaling was controlled by PI3K and Rheb-GTP, basal initia-
tion was controlled by a fragile balance between the induction of Rheb-GTP and
the restraint of PTEN.
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Though the initiation model was assembled from an extensive literature re-
view, several potentially important signaling mechanisms were not included.
First, we should revisit the role PRAS40. Currently, PRAS40 acts as a cofactor
that aids in pAkt (Ser473)-mediated activation of mTORC1. Sancak et al sug-
gested that PRAS40 sequestersmTORC1, and only after phosphorylation byAkt
releases from mTORC1 [94]. Other groups have also shown that mTORC1 can
phosphorylate and inhibit PRAS40, thus providing a positive-feedback mecha-
nism for Akt-mediated mTORC1 activation [30, 127]. A more complete descrip-
tion of PRAS40 will enhance our ability to interrogate Akt dependent mTORC1
activation. Second, we need to refine the description of IRS1 feedback. Cur-
rently, we assume a single deactivating phosphorylation event at Ser308. How-
ever, several studies have shown that IRS1 can be phosphorylated at multiple
serine sites, which are both activating and deactivating [79, 37]. Additionally,
PTEN is known to dephosphorylate activated Platelet-derived Growth Factor
(PDGF) receptors and attenuate their activity, a feature not included currently
[114]. A more complete description of IRS1 phosphorylation could help define
how (and under what conditions) IRS1 regulation attenuates PI3K activation.
Third, we modeled the regulation of 4E-BPx as a single phosphorylation event
where phosphorylated 4E-BPx was unable to bind to eIF4E. In reality, 4E-BPx
family members, such as 4E-BP1, have several phosphorylation sites [81] and
the release of eIF4E is driven only after multiple conserved phosphorylation
events [36]. Additionally, eIF4E can itself be phosphorylated at Ser209; while
there is agreement that the phosphorylation of eIF4E does have a regulatory
significance, the data is contradictory as to whether it is positive or negative
[100]. Fourth, signaling downstream of mTORC1 has also been shown to medi-
ate translation modes beyond those included in our model. eIF3 has been iden-
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tified as a scaffolding protein that recruits mTORC1 to untranslated mRNA and
facilitates S6K1 and 4E-BP1 phosphorylation [45]. S6K1 can also activate eIF4B,
a protein that helps eIF4A to unwind the secondary structure of untranslated
mRNA [82]. Further, a recently discovered scaffold protein, SKAR, has been
shown to assist S6K1 recruitment to mRNA [68]. Lastly, because of mTORC1’s
unique role in cellular metabolism it would be interesting to explore how other
aspects of metabolism interact with insulin signaling to mediate decisions be-
tween translation, lipid synthesis and proliferation.
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2.4 Materials and Methods
2.4.1 Formulation and solution of the model equations.
The translation initiation model was formulated as a set of coupled non-linear
ordinary differential equations (ODEs):
dx
dt
= S · r (x,p) x (to) = xo (2.1)
The symbol S denotes the stoichiometric matrix (250 × 573). The quantity x
denotes the concentration vector of proteins (250 × 1). The term r (x,p) denotes
the vector of reaction rates (573 × 1). Each row in S described a protein, while
each column described the stoichiometry of network interactions. Thus, the (i, j)
element of S, denoted by σi j, described how protein i was involved in rate j. If
σi j < 0, then protein i was consumed in r j. Conversely, if σi j > 0, protein i was
produced by r j. Lastly, if σi j = 0, then protein iwas not involved in rate j.
We assumed mass-action kinetics for each interaction in the network. The
rate expression for interaction qwas given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−σ jqj (2.2)
The set
{
Rq
}
denotes reactants for reaction q while σ jq denotes the stoichiomet-
ric coefficient (element of the matrix S) governing species j in reaction q. All
reversible interactions were split into two irreversible steps. The mass-action
formulation, while expanding the dimension of the initiation model, regular-
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ized themathematical structure; this allowed automatic generation of themodel
code using UNIVERSAL and regularized the unknown model parameters (pa-
rameters were one of only three types, association, dissociation or catalytic
rate constants). UNIVERSAL, an open source Objective-C/Java code generator
which generates model code from text and SBML inputs, is freely available as a
Google Code project (http://code.google.com/p/universal-code-generator/).
The model equations were solved using the LSODE routine in OCTAVE (v
3.0.5; www.octave.org) on an Apple workstation (Apple, Cupertino, CA; OS
X v10.6.4).
When calculating the response of the model to the addition of insulin or
other growth factors, we first ran to steady-state and then issued the pertur-
bation. The steady-state was estimated numerically by repeatedly solving the
model equations and estimating the difference between subsequent time points:
‖x (t + ∆t) − x (t) ‖2 ≤ γ (2.3)
The quantities x (t) and x (t + ∆t) denote the simulated concentration vector at
time t and t + ∆t, respectively. The L2 vector-norm was used as the distance
metric, where ∆t = 1 s and γ = 0.001 for all simulations.
2.4.2 Estimation and cross-validation of a population ofmodels
using Pareto Optimal Ensemble Techniques (POETs).
POETs is a multiobjective optimization strategy which integrates several local
search strategies e.g., Simulated Annealing (SA) or Pattern Search (PS) with a
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Pareto-rank-based fitness assignment [107]. Denote a candidate parameter set
at iteration i + 1 as ki+1. The squared error for ki+1 for training set j was defined
as:
E j(k) =
T j∑
i=1
(
Mˆi j − yˆi j(k)
)2
(2.4)
The symbol Mˆi j denotes scaled experimental observations (from training set j)
while the symbol yˆi j denotes the scaled simulation output (from training set
j). The quantity i denotes the sampled time-index and T j denotes the number
of time points for experiment j. The read-out from the training immunoblots
was band intensity estimated using the ImageJ software package. The scaled
measurement for species x at time i = {t1, t2, .., tn} in condition j is given by:
Mˆi j = Mi j −miniMi jmaxiMi j −miniMi j (2.5)
Under this scaling, the lowest intensity band equaled zero while the highest
intensity band equaled one. A similar scaling was defined for the simulation
output.
We computed the Pareto rank of ki+1 by comparing the simulation error at it-
eration i+1 against the simulation archiveKi. We used the Fonseca and Fleming
ranking scheme [31]:
rank (ki+1 | Ki) = p (2.6)
where p denotes the number of parameter sets that dominate parameter set ki+1.
Parameter sets on or near the optimal trade-off surface have small rank. Sets
with increasing rank are progressively further away from the optimal trade-
off surface. The parameter set ki+1 was accepted or rejected by the SA with
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probability P (ki+1):
P(ki+1) ≡ exp {−rank (ki+1 | Ki) /T } (2.7)
where T is the computational annealing temperature. The initial temperature
To = n/log(2), where n is user defined (n = 4 for this study). The final temper-
ature was T f = 0.1. The annealing temperature was discretized into 10 quanta
between To and T f and adjusted according to the schedule Tk = βkT0 where β
was defined as:
β =
(
T f
To
)1/10
(2.8)
The epoch-counter k was incremented after the addition of 100 members to the
ensemble. Thus, as the ensemble grew, the likelihood of accepting parameter
sets with a large Pareto rank decreased. To generate parameter diversity, we
randomly perturbed each parameter by ≤ ±25%. We performed a local pattern-
search every q steps to minimize the residual for a single randomly selected
objective. The local pattern-search algorithm has been described previously [33,
123]. The parameter ensemble used in the simulation and sensitivity studies
was generated from the low-rank parameter sets in Ki.
A leave-three-out cross-validation strategy was used to simultaneously cal-
culate the training and prediction error during the parameter estimation pro-
cedure [60]. The 24 training data sets were partitioned into eight subsets, each
containing 21 data sets for training and three data sets for validation. The leave-
three-out scheme generated 18,886 probable models, from which we selected
a subset for further study. From the rank zero models, we iteratively selected
50 random models from each cross-validation trial with the lowest correlation
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and shortest euclidian distance to the origin (minimum error). This selection
technique produced sub-ensembles with low set-to-set correlation (≤ 0.50) and
minimum training error.
2.4.3 Sensitivity and robustness analysis of the initiation
model population.
Sensitivity coefficients were calculated as shown previously [108, 107, 117] for 40
models selected from the ensemble (rank-zero, low-correlation, minimum error
selection). The resulting sensitivity coefficients were scaled and time-averaged
(Trapezoid rule):
Ni j ≡ 1T
∫ T
0
dt · |αi j (t) si j(t)| (2.9)
where T denotes the final simulation time and αi j = 1. The time-averaged sensi-
tivity coefficients were then organized into an array for each ensemble member:
N () =

N ()11 N ()12 . . . N ()1 j . . . N ()1P
N ()21 N ()22 . . . N ()2 j . . . N ()2P
...
...
...
...
N ()M1 N ()M2 . . . N ()M j . . . N ()MP

 = 1, 2, . . . ,N (2.10)
where  denotes the index of the ensemble member, P denotes the number of pa-
rameters, N denotes the number of ensemble samples and M denotes the num-
ber of model species. To estimate the relative fragility or robustness of species
and reactions in the network, we decomposed the N () matrix using Singular
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Value Decomposition (SVD):
N () = U()Σ()VT,() (2.11)
Coefficients of the left (right) singular vectors corresponding to largest β sin-
gular values of N () were rank-ordered to estimate important species (reaction)
combinations. Only coefficients with magnitude greater than a threshold (δ =
0.001) were considered. The fraction of the β vectors in which a reaction or
species index occurred was used to rank its importance.
Robustness coefficients were calculated as shown previously [118]. Robust-
ness coefficients (denoted by α
(
i, j, to, t f
)
) are the ratio of the integrated concen-
tration of a network marker in the presence (numerator) and absence (denomi-
nator) of structural or operational perturbation. The quantities t0 and t f denote
the initial and final simulation time respectively, while i and j denote the indices
for the marker and the perturbation respectively. If α
(
i, j, to, t f
)
> 1, then the
perturbation increased the marker concentration. Conversely, if α
(
i, j, to, t f
)
 1
the perturbation decreased the marker concentration. Lastly, if α
(
i, j, to, t f
)
∼ 1
the perturbation did not influence the marker concentration. The α
(
i, j, to, t f
)
were calculated over 400 models selected from the ensemble (rank-zero, low-
correlation, minimum error selection).
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CHAPTER 3
SUMMARY AND FUTURE DIRECTIONS
In the previous sections we have developed a mathematical model of eu-
karyotic translation initiation. We have used this model to identify the impor-
tant network components under basal and insulin-induced signaling. We have
also analyzed the ability of the system to respond to various network perturba-
tions. Our observations correspond to those observed in vitro and can be used
to clarify disease states associated with insulin-mediated translation initiation
malfunction.
As stated previously, mechanistic models are used to gain insight into the
dynamics and function of complex biological systems. As systems become in-
creasingly complex, mechanistic models become an irreplaceable tool towards
understanding network function. Yet, understanding complex systems requires
models and computational tools to become equally complex. If biologists and
engineers hope to understand some of the most complex biological systems,
models must become larger and analytical tools must improve. Models must
incorporate more pathways, more signaling events, more ligands, and more
regulatory components in order to truly capture the complexity of biological
behavior. Systems biology must integrate up the length scale, towards the scale
of cells, tissues, organs or entire organisms. Both the models and the scope of
measurement must increase. Systems biologists must echo the timeless conclu-
sion of every man who is stuck at the bottom of a well, “the only way out is
up”.
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Figure 3.1: The Hallmarks of Cancer. Used from Hanahan and Wein-
berg, 2000 [39]
3.1 Translation initiation in cancer
One direction of model expansion is in the realm of cancer. Of all biological sys-
tems, cancer is the most infamous for its immense complexity. The emergence
of cancer is marked by numerous hallmarks such as insensitivity to anti-growth
signals, limitless replicative potential, sustained angiogenesis and metastasis
(Fig. 3.1) [39]. Understanding the signaling underlying these phenotypes is not
a trivial task. Mathematical models will be irreplaceable as researchers try to in-
vestigate how these phenotypes arise from both genotype and external stimuli
upon the cell.
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The Varner Laboratory has several publications and current projects investi-
gating aspects of the cancer phenotype. Mathematical models have been pub-
lished on prostate cancer, cell-cycle and apoptosis [117, 76, 32] with current
projects investigating angiogenesis, breast cancer, and TNFα signaling. Integra-
tion of these models together, will provide a useful framework for interrogating
the exact mechanisms and pathways that can lead to cancer.
Such integration however, is far from trivial. As models become larger, prob-
lems of parameter identifiability and model validation abound. Further, ad-
vanced computational methods and faster mathematical solvers are imperative
for model development and analysis. Models of this size also place a premium
of high-quality quantitative data that can be used to train a model accurately.
3.2 Metabolic regulation
mTOR has long been recognized as a nutrient sensor and a regulator of growth.
In addition to translation-initiation, mTOR is associated with numerous meth-
ods of nutrient sensing and regulation (Fig. 3.2). Amino-acids and glucose can
also induce mTOR activity [133]. mTOR has also been shown to upregulate
genes associated with lipid synthesis, metabolism, proliferation and apoptosis
[133]. Incorporation of these pathways could help to understand how mTOR
regulates diverse metabolic pathways.
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Figure 3.2: The mTOR Signaling Pathway. Used from Zoncu et al. 2010
[133]
3.3 Final Thoughts
Systems biology has seen huge advancements in the past decade. It has grown
from an offshoot of molecular biology into a field of its own. Systems biology
now has its own conferences, research centers and academic departments. Yet
these strides forward have been met with new challenges. Researchers have
recognized that quality of data is favored over quantity of data and have be-
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gun to develop more accurate ‘omics’ technologies. Further, the difficulties of
systems approaches has constrained the fields growth. Kitano states it simply,
”Genomics exploded, because if you buy a sequencing machine, anyone can do
it. But having to combine good biology with good mathematical modeling isn’t
easy” [69].
Nonetheless, systems biology continues to move forward. In a recent essay
in the biological journal Cell, Adam Arkin and David Schaffer conclude,
“As systems biology matures, the number of studies linking correlation
with causation and principles with prediction continues to grow... Ad-
vances in measurement technologies that enable large-scale experiments
across an array of parameters and conditions will increasingly meld these
correlative and causal approaches, including correlative analyses leading to
mechanistic hypothesis testing as well as causal models empowered with
sufficient data to make predictions... The increasing integration of experi-
mental and computational technologies will thus corroborate, deepen, and
diversify the theories that the earliest systems biologists used logic to infer,
thereby inching us ever closer to that central question: “What is Life”?” [3]
Even seventy years later, the timeless question of Erwin Schro¨dinger re-
mains. How do we explain our own existence? How does our simple genetic
code result in what we commonly refer to as life? I expect that these questions
will never be fully answered to our satisfaction. Reflections on the purpose and
meaning of life have have intrigued theologians and philosophers for millennia.
Yet, that should not deter us from investigation. We’ve been given the tools to
explore, perhaps its about time we get back to digging.
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APPENDIX A
ABBREVIATIONS
Table A.1: Abbreviations and Species Names
Abbreviation Species Name
IGF1 Insulin-like Growth Factor 1
IGF1R Insulin-like Growth Factor Receptor
IRA Insulin Receptor
SHP2 SH2-domain-containing tyrosine phosphatase-2
Grb2 growth-factor-receptor-bound protein-2
Shc Src-homology-2-containing protein
SoS son-of-sevenless
SOCS1/3 suppressor of cytokine signaling-1/3
PTP1B protein tyrosine phosphatase-1B
Grb10 growth-factor-receptor-bound protein 10
PC1 plasma-cell-membrane glycoprotein-1
IRS1 insulin-receptor substrate 1
pIRS1 inhibitory IRS1 phosphorylation
PTEN phosphatase and tensin homologue
PIP2 0hosphatidylinositol 4,5-bisphosphate
PIP3 phosphatidylinositol-3,4,5-triphosphate
PI3K Phosphatidylinositol 3-kinase
Pdk1 phosphoinositide-dependent kinase 1
Pdk1:m Membrane-associated Pdk1
Akt:m Membrane-associated Akt
pAkt(Thr308) Phosphorylated Akt(Thr308)
pAkt(Ser473) Phosphorylated Akt(Ser473)
rictor rapamycin-insensitive companion of mTOR
SIN1 mammalian stress-activated map kinase-interacting protein 1
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mLST8 mammalian lethal with SEC13 protein 8
mTOR mammalian target of rapamycin
mTORC2 mTOR complex 2
TSC1/2 tuberous sclerosis 1/2 complex
pTSC1/2 inhibitory TSC1/2 phosphorylation
raptor regulatory associated protein of mTOR
Rheb Ras homologue enriched in brain
mTORC1 mTOR complex 1
4E-BP1 eIF4E-binding protein 1
eIF4E eukaryotic translation initiation factor 4E
S6K1 S6 kinase 1
pS6K1 Activated S6K1 phosphorylation
eIFx eukaryotic translation initiation factor
PABP Poly(A) binding protein
AUG initiation codon
40S 40S ribosomal subunit
1 eukaryotic translation initiation factor 1
met-tRNA anticodon loop of initiator tRNA
GDP Guanosine diphosphate
GTP Guanosine triphosphate
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